Technology
multiplex protein biomarker signatures in urine samples to detect cancer
Our diagnostic technology is based on:
10-Protein Biomarker Signature
Clinical Variables
Proprietary Computational Algorithms
Actionable Clinical Score
The goal of liquid biopsies is to move the standard of care away from subpar, outdated urine tests to a modern, accurate urinalysis.
Nonagen Bioscience® has developed a proprietary panel of 10 cancer-associated protein biomarkers characterized by differential expression patterns associated with bladder cancer. The biomarker signature has been extensively validated through clinical research and collaborations with leading academic and research institutions.
These proteins represent diverse biological processes involved in cancer development and progression, including cell proliferation, migration, angiogenesis, and tumor–host interactions.
Nonagen's AI-enabled computational diagnostics platform integrates the multiplex protein signature with relevant clinical data to generate indication-specific risk scores. Data are securely analyzed within a HIPAA-compliant cloud environment (AWS), enabling the Oncuria® platform to produce individualized clinical reports within minutes.
These reports provide actionable information regarding a patient's likelihood of harboring bladder cancer and are designed to support clinical decision-making and patient management.
The Oncuria® White Paper
Learn how the Oncuria® multiplex immunoassay and proprietary computational platform were developed, clinically validated, and compared with existing urine-based tests for bladder cancer.
Download Now